Search | Invivogen

VET-SAP® saponin adjuvant

Saponin vaccine adjuvant - CAS #8047-15-2

Default product image

CL429 VacciGrade™ - TLR2 & NOD2-based Adjuvant

Pam2C-conjugated murabutide

Dose-dependent NF-κB response to CL429 in HEK-Blue™ hTLR2 and HEK-Blue™ hNOD2 cells

CL429 chemical structure

Pam3CSK4 VacciGrade™ - TLR2/TLR1-based Adjuvant

Synthetic triacylated lipopeptide | Th1 response

Evaluation of NF-κB activation with Pam3CSK4

Specificity of Pam3CSK4 activation

ODN 1585 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Mouse) | Th1 response

Dose-dependent NF-κB response of ODN 1585 in HEK-Blue™ mTLR9 cells

NF-κB and IRF responses of ODN 1585 in THP1-Dual™ hTLR9 cells

CL413 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Chimeric molecule | Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

CL413 chemical structure

CL401 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Pam2C-conjugated 8-hydroxyadenine| Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

Anti-OVA mIgG levels at 15, 30 and 45 days after the initial immunization in different groups.

Anti-OVA total IgG, IgG1, and IgG2a levels 45 days after the initial immunization in different groups.

Quil-A® adjuvant

Saponin vaccine adjuvant

Default product image

LPS-B5 (LPS from E. coli O55:B5) - TLR4 Agonist

Standard and ultrapure lipopolysaccharide from E. coli O55:B5

LPS-B5 Standard-dependent activation of TLR2 and TLR4

LPS-B5 UP-dependent activation of TLR4

LPS-EB VacciGrade™ - TLR4-based Adjuvant

Lipopolysaccharide from E. coli 0111:B4 | Th1 response

LPS-EB Vaccigrade™-dependent activation of TLR4

TDB VacciGrade™ - Mincle-based Adjuvant

Synthetic analog of the cord factor | Th1 response

TDB dose-dependent activation of Mincle

ODN 2395 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class C (Human/mouse) | Th1 response

NF-κB response in HEK-Blue™-derived cells upon ODN 2395 stimulation

NF-κB and IRF response upon ODN 2395 stimulation

CFA

Complete Freund’s Adjuvant | Th1 response

Anti-Ova mIgG levels at 15 and 30 days after the initial immunization with CFA

OVA peptides

Two OVA peptide standards for ELISPOT

Default product image

OVA protein

OVA (ovalbumin) for in vitro use

Default product image

EndoFit™ OVA protein

OVA (ovalbumin) for in vivo use

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with IFA

R848 VacciGrade™ - TLR7/8-based Adjuvant

Imidazoquinoline compound | Th1 response

NF-κB response of HEK-Blue™-derived cells to R848

NF-κB and IRF responses of THP1-Dual™-derived cells to R848

Poly(I:C) (HMW) VacciGrade™ - TLR3-based Adjuvant

Polyinosine-polycytidylic acid | Th1 response

Dose-dependent activation of TLR3

ODN 2006 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Human) | Th1 response

Species-driven TLR9 differential responses

NF-κB response induced by ODN 2006

IRF response induced by ODN 2006

MPLA Synthetic - TLR4 Agonist

Synthetic monophosphoryl lipid A

MPLAs dose-dependent activation of TLR4

MPLA-SM - TLR4 Agonist Preparation

Monophosphoryl lipid A from Salmonella minnesota R595

Activation of mouse and human TLR4

Absence of TLR2-activating contaminants